DOP2011000129A - 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6 - Google Patents
1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6Info
- Publication number
- DOP2011000129A DOP2011000129A DO2011000129A DO2011000129A DOP2011000129A DO P2011000129 A DOP2011000129 A DO P2011000129A DO 2011000129 A DO2011000129 A DO 2011000129A DO 2011000129 A DO2011000129 A DO 2011000129A DO P2011000129 A DOP2011000129 A DO P2011000129A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- formula
- compounds
- cancer
- present
- kinase inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical group C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a inhibidores de cinasa p70 S6 y AKT de la fórmula: Fórmula I caracterizado porque es [5-(4-etil-piperazin-1-ilmetil)-piridin-2-il]-[5-fluoro-4-(7-fluoro-3-isopropil-2-metil-3H-benzoimidazol-5-il)-pirimidin-2-il]-amina. La presente invención también proporciona composiciones farmacéuticas que comprenden compuestos de Fórmula I, usos de compuestos de Fórmula I y métodos para usar compuestos de Fórmula I. Los compuestos de la presente invención son útiles en el tratamiento de cáncer, particularmente cáncer colorectal, cáncer de mama, cáncer de pulmón, especialmente cáncer de pulmón de células no pequeñas (NSCLC), cáncer de próstata, gioblastoma, linfoma de células del manto (MCL), leucemia mieloide crónica (CML) y leucemia mieloide aguda (AML).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11327308P | 2008-11-11 | 2008-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000129A true DOP2011000129A (es) | 2016-02-29 |
Family
ID=41402451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000129A DOP2011000129A (es) | 2008-11-11 | 2011-05-09 | 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8148387B2 (es) |
| EP (1) | EP2358710B1 (es) |
| JP (1) | JP5432275B2 (es) |
| KR (1) | KR101334460B1 (es) |
| CN (1) | CN102216302B (es) |
| AR (1) | AR074072A1 (es) |
| AU (1) | AU2009314324B2 (es) |
| BR (1) | BRPI0921916A2 (es) |
| CA (1) | CA2743019C (es) |
| CO (1) | CO6382114A2 (es) |
| CR (1) | CR20110240A (es) |
| CY (1) | CY1113409T1 (es) |
| DK (1) | DK2358710T3 (es) |
| DO (1) | DOP2011000129A (es) |
| EA (1) | EA018947B1 (es) |
| EC (1) | ECSP11011048A (es) |
| ES (1) | ES2391704T3 (es) |
| HN (1) | HN2011001247A (es) |
| HR (1) | HRP20120738T1 (es) |
| IL (1) | IL211940A (es) |
| JO (1) | JO2822B1 (es) |
| MA (1) | MA32776B1 (es) |
| MX (1) | MX2011005000A (es) |
| MY (1) | MY161461A (es) |
| NZ (1) | NZ592062A (es) |
| PA (1) | PA8846901A1 (es) |
| PE (1) | PE20110807A1 (es) |
| PL (1) | PL2358710T3 (es) |
| PT (1) | PT2358710E (es) |
| RS (1) | RS52520B (es) |
| SI (1) | SI2358710T1 (es) |
| TN (1) | TN2011000207A1 (es) |
| TW (1) | TWI422587B (es) |
| UA (1) | UA100190C2 (es) |
| WO (1) | WO2010056563A1 (es) |
| ZA (1) | ZA201102549B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597579A (en) | 2009-07-02 | 2013-06-28 | Sanofi Sa | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors |
| EP2491032B1 (en) * | 2009-10-23 | 2014-04-16 | Eli Lilly and Company | Akt inhibitors |
| PH12013502073A1 (en) | 2011-04-07 | 2014-01-13 | Bayer Ip Gmbh | Imidazopyridazines as akt kinase inhibitors |
| JP5695800B2 (ja) * | 2011-07-09 | 2015-04-08 | 山東軒竹医薬科技有限公司 | ジペプチジルペプチダーゼ−ｉｖ阻害剤の塩の結晶形ｉ、及びその製造方法並びにその応用 |
| SG2014009278A (en) | 2011-09-12 | 2014-07-30 | Merck Patent Gmbh | Novel imidazole amines as modulators of kinase activity |
| HUE034979T2 (en) | 2011-09-12 | 2018-05-02 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| AU2013344549B2 (en) * | 2012-11-16 | 2018-03-08 | Xiaoling Chen | Novel imidazol-piperidinyl derivatives as modulators of kinase activity |
| US9580443B2 (en) | 2012-11-16 | 2017-02-28 | Merck Patent Gmbh | Heterocyclic derivatives as modulators of kinase activity |
| WO2014143612A1 (en) * | 2013-03-11 | 2014-09-18 | Merck Patent Gmbh | 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
| EP3105224A1 (en) * | 2014-02-11 | 2016-12-21 | Merck Patent GmbH | Pyrimidine imidazole amines as modulators of kinase activity |
| TW201718574A (zh) | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Ｃｇｒｐ受體拮抗劑 |
| PT3459953T (pt) * | 2016-05-20 | 2021-07-29 | Taiho Pharmaceutical Co Ltd | Novo derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona |
| KR20220154722A (ko) * | 2020-03-17 | 2022-11-22 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 융합된 이환식 유도체, 이의 제조 방법, 및 이의 약학적 용도 |
| CN113444110B (zh) * | 2020-03-25 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| TW202328138A (zh) | 2021-09-17 | 2023-07-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 稠合二環類衍生物的可藥用鹽、晶型及其製備方法 |
| WO2024009977A1 (ja) * | 2022-07-05 | 2024-01-11 | 大鵬薬品工業株式会社 | ５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン及びその塩体の結晶 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| WO2006091450A1 (en) * | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
-
2009
- 2009-10-28 AR ARP090104158A patent/AR074072A1/es unknown
- 2009-10-29 JO JO2009400A patent/JO2822B1/en active
- 2009-10-29 TW TW098136731A patent/TWI422587B/zh not_active IP Right Cessation
- 2009-10-29 PA PA20098846901A patent/PA8846901A1/es unknown
- 2009-11-03 CN CN2009801449532A patent/CN102216302B/zh active Active
- 2009-11-03 SI SI200930348T patent/SI2358710T1/sl unknown
- 2009-11-03 MX MX2011005000A patent/MX2011005000A/es active IP Right Grant
- 2009-11-03 KR KR1020117010569A patent/KR101334460B1/ko not_active Expired - Fee Related
- 2009-11-03 MY MYPI2011002030A patent/MY161461A/en unknown
- 2009-11-03 BR BRPI0921916A patent/BRPI0921916A2/pt not_active IP Right Cessation
- 2009-11-03 JP JP2011536383A patent/JP5432275B2/ja active Active
- 2009-11-03 EP EP09744896A patent/EP2358710B1/en active Active
- 2009-11-03 DK DK09744896.3T patent/DK2358710T3/da active
- 2009-11-03 PE PE2011001018A patent/PE20110807A1/es not_active Application Discontinuation
- 2009-11-03 PT PT09744896T patent/PT2358710E/pt unknown
- 2009-11-03 HR HRP20120738AT patent/HRP20120738T1/hr unknown
- 2009-11-03 RS RS20120443A patent/RS52520B/en unknown
- 2009-11-03 ES ES09744896T patent/ES2391704T3/es active Active
- 2009-11-03 PL PL09744896T patent/PL2358710T3/pl unknown
- 2009-11-03 UA UAA201105367A patent/UA100190C2/ru unknown
- 2009-11-03 EA EA201170680A patent/EA018947B1/ru not_active IP Right Cessation
- 2009-11-03 AU AU2009314324A patent/AU2009314324B2/en not_active Ceased
- 2009-11-03 NZ NZ592062A patent/NZ592062A/xx not_active IP Right Cessation
- 2009-11-03 CA CA2743019A patent/CA2743019C/en not_active Expired - Fee Related
- 2009-11-03 WO PCT/US2009/063020 patent/WO2010056563A1/en active Application Filing
- 2009-11-03 US US12/611,139 patent/US8148387B2/en active Active
-
2011
- 2011-03-24 IL IL211940A patent/IL211940A/en not_active IP Right Cessation
- 2011-04-06 ZA ZA2011/02549A patent/ZA201102549B/en unknown
- 2011-04-25 TN TN2011000207A patent/TN2011000207A1/fr unknown
- 2011-05-03 HN HN2011001247A patent/HN2011001247A/es unknown
- 2011-05-06 CR CR20110240A patent/CR20110240A/es unknown
- 2011-05-09 DO DO2011000129A patent/DOP2011000129A/es unknown
- 2011-05-09 MA MA33822A patent/MA32776B1/fr unknown
- 2011-05-11 EC EC2011011048A patent/ECSP11011048A/es unknown
- 2011-05-12 CO CO11058555A patent/CO6382114A2/es active IP Right Grant
-
2012
- 2012-10-05 CY CY20121100928T patent/CY1113409T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000129A (es) | 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6 | |
| PE20090156A1 (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas | |
| MX2022002581A (es) | Compuestos de benzimidazol como inhibidores de c-kit. | |
| MX2010003668A (es) | Derivados de purina sustituidas con primidina. | |
| PE20070496A1 (es) | Compuestos derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina | |
| PE20141381A1 (es) | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer | |
| MX353308B (es) | Derivados fosforosos como inhibidores de cinasa. | |
| CR20110620A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus | |
| CU20120042A7 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| EP2614051A4 (en) | P53-MDM2 ANTAGONISTS | |
| JO3073B1 (ar) | مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3 | |
| WO2015154064A3 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
| NZ620020A (en) | Heterocyclic compounds and uses thereof | |
| CR20140378A (es) | Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf | |
| MX2009008981A (es) | Prediccion de respuesta a un inhibidor her. | |
| CR10995A (es) | Inhibidores de la actividad de akt | |
| CO6771441A2 (es) | Compuestos de triazolopiridina como inhibidores de cinasa pim | |
| NZ620000A (en) | Prodrug forms of kinase inhibitors and their use in cancer therapy | |
| CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| NI201000002A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k. | |
| MY163477A (en) | Pyrimidinyl-pyridazinone derivatives | |
| MY155719A (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| MX347765B (es) | Inhibidores macrociclicos de la quinasa flt3. |